AMINOSYN-HBC 7%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN-HBC 7% (AMINOSYN-HBC 7%).
Aminosyn-HBC 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, supporting anabolism and tissue repair in patients with high metabolic stress.
| Metabolism | Amino acids are metabolized via nitrogen transamination and deamination, with carbon skeletons entering the citric acid cycle or gluconeogenesis; hepatic and renal metabolism predominant. |
| Excretion | Renal: >90% as amino acids and metabolites; minimal biliary/fecal elimination. |
| Half-life | Not applicable; amino acids are continuously metabolized and recycled. For individual amino acids, terminal half-life ranges from minutes to hours depending on metabolic demand. |
| Protein binding | Minimal (<10%); free amino acids bind to plasma proteins such as albumin and globulins. |
| Volume of Distribution | 0.5-0.7 L/kg; distributes into total body water and tissues, reflecting rapid cellular uptake. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: Plasma amino acid levels rise within minutes; clinical effect on nitrogen balance observed within 24-48 hours. |
| Duration of Action | Intravenous: Duration depends on infusion rate and metabolic utilization; continuous infusion maintains effect. After cessation, nitrogen retention persists for 12-24 hours. |
Intravenous infusion; typical adult dose: 1.0-1.5 g/kg/day of amino acids, administered as a continuous infusion over 12-24 hours.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-60 mL/min: reduce dose by 50%; for GFR <30 mL/min: use with caution, monitor amino acid levels, consider dialysis adjustments. |
| Liver impairment | Child-Pugh Class B or C: initiate at 0.5-0.8 g/kg/day and titrate based on tolerance and ammonia levels. |
| Pediatric use | Neonates and infants: 2.0-3.0 g/kg/day; children: 1.5-2.5 g/kg/day; administered as continuous intravenous infusion. |
| Geriatric use | Start at low end of adult range (1.0 g/kg/day) and adjust based on renal function due to age-related decline; monitor for fluid overload and electrolyte imbalances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN-HBC 7% (AMINOSYN-HBC 7%).
| Breastfeeding | Excretion in human milk unknown. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. M/P ratio not determined. Limited data suggest amino acid infusion does not significantly alter milk composition with short-term use. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies not conducted. Essential amino acid infusions are generally considered low risk; however, the product contains electrolytes and has not been specifically studied for teratogenicity. Use only if clearly needed. First trimester: unknown risk; second and third trimesters: theoretical risk of electrolyte imbalance affecting fetal development if maternal homeostasis not maintained. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component.","Severe hepatic encephalopathy.","Inborn errors of amino acid metabolism (e.g., maple syrup urine disease).","Severe renal failure without dialysis."]
| Precautions | ["Use with caution in patients with renal insufficiency or hepatic impairment due to risk of nitrogen intolerance.","Monitor serum electrolytes, blood glucose, and acid-base balance.","Risk of hyperammonemia with prolonged use.","Do not administer simultaneously with blood products through same IV line due to risk of incompatibility."] |
| Food/Dietary | Aminosyn-HBC 7% is used in parenteral nutrition; oral food intake is typically not applicable during infusion. However, when transitioning to oral diet, high-protein foods may need to be adjusted based on metabolic status. No specific food interactions; monitor overall electrolyte and fluid balance. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, blood glucose, acid-base balance, renal function, and fluid status. Fetal monitoring indicated if maternal condition deteriorates. Assess for signs of hyperammonemia or metabolic acidosis. |
| Fertility Effects | No studies on fertility effects. No known impact on reproduction. Essential amino acids are not expected to adversely affect fertility. |
| Clinical Pearls | Aminosyn-HBC 7% is a hypertonic amino acid solution (700 mOsm/L) used in parenteral nutrition, especially for patients with high metabolic needs. Administer via central venous catheter due to high osmolarity. Monitor blood urea nitrogen and ammonia levels; contraindicated in hepatic coma or severe renal failure. Use with caution in patients with electrolyte imbalances or fluid overload. |
| Patient Advice | This medication is given intravenously and requires careful medical supervision. · Report any signs of infection at the infusion site, such as redness, swelling, or pain. · Tell your doctor if you experience nausea, vomiting, headache, or confusion. · Do not stop the infusion abruptly; it is part of your total nutrient supply. · Inform your healthcare provider of all other medications you are taking, including prescription and over-the-counter drugs. |